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In the course of breast cancer global gene expression studies, we identified an uncharacterized gene known 
as RHBDD2 (Rhomboid domain containing 2) to be markedly over-expressed in primary tumors from patients 
with recurrent disease. In this study, we identified RHBDD2 mRNA and protein expression significantly 
elevated in breast carcinomas compared with normal breast samples as analyzed by SAGE (n =46) and 
immunohistochemistry (n = 213). Interestingly, specimens displaying RHBDD2 over-expression were 
predominantly advanced stage III breast carcinomas (p = 0.001). Western-blot, RT-PCR and cDNA sequencing 
analyses allowed us to identify two RHBDD2 alternatively spliced mRNA isoforms expressed in breast cancer 
cell lines. We further investigated the occurrence and frequency of gene amplification and over-expression 
affecting RHBDD2 in 131 breast samples. RHBDD2 gene amplification was detected in 21% of 98 invasive 
breast carcinomas analyzed. However, no RHBDD2 amplification was detected in normal breast tissues 
(n = 17) or breast benign lesions (n = 16) (p = 0.014). Interestingly, siRNA-mediated silencing of RHBDD2 
expression results in a decrease of MCF7 breast cancer cells proliferation compared with the corresponding 
controls (p = 0.001). In addition, analysis of publicly available gene expression data showed a strong 
association between high RHBDD2 expression and decreased overall survival (p = 0.0023), relapse-free 
survival (p = 0.0013), and metastasis-free interval (p = 0.006) in patients with primary ER-negative breast 
carcinomas. In conclusion, our findings suggest that RHBDD2 over-expression behaves as an indicator of poor 
prognosis and may play a role facilitating breast cancer progression.
© 2009 Elsevier B.V. All rights reserved.
1. Introduction
In the course of recent breast cancer global gene expression studies 
we identified a distantly related rhomboid-like gene known as RHBDD2 
(Rhomboid domain containing2) located at the 7qll.23 chromosomal 
region, to be markedly over-expressed in primary invasive carcinomas 
from patients that recurred within 6 years of follow-up [1].
The human genome contains several rhomboid-like genes which 
can be phylogenetically grouped in three major classes [2]. The first 
class, includes the true active rhomboids genes that are subdivided into 
secretase (e.g. RHBDL-1/-2/-3 and RHBDD1 genes) and L’ARL-type 
subfamilies. The second class is composed of novel inactive rhomboids 
members, recently named as iRhoms group (e.g. RHBDF-1/-2 genes). 
The third group includes a small number of other distant evolutionary 
related and uncharacterized genes (e.g. RHBDD-2/-3f for which there 
is no evidence that they are active proteases. Rhomboid-like proteins 
function in diverse processes including quorum sensing in bacteria, 
mitochondrial membrane fusion/apoptosis (PARLf and stem cell diffe­
rentiation in eukaryotes [3,4]. Also, rhomboid-like proteins have been 
recently linked to human diseases, including early-onset blindness, 
diabetes, and parasitic diseases [5]. However, the biological functions of 
the mammalian rhomboid-like family remains to be determined.
Here we present data supporting the role of RHBDD2 as a novel 
breast cancer-related gene. We demonstrate that RHBDD2 is over­
expressed at the mRNA and protein levels in breast cancer samples and 
in some of these cases due to gene amplification. Interestingly, analysis 
of publicly available breast cancer gene expression databases indicates 
that RHBDD2 is over-expressed in estrogen receptor-negative breast 
carcinomas from patients with poor prognosis. Finally, we show that in 
vitro RHBDD2 silencing regulates cell proliferation of breast cancer cells.
2. Material and methods
2.1. Serial analysis of gene expression database mining
To perform a comparative analysis of the human Rhomboid-like 
family members expressed in breast tissue, we analyzed 46 breast 
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SAGE (serial analysis of gene expression) libraries: 4 normal breast 
epithelium, 8 ductal carcinoma in situ (DCIS), and 33 invasive ductal 
carcinomas (IDC). To this end, we combined 29 breast cancer SAGE 
libraries generated by us at a resolution of 100,000 tags per library 
(Aldaz Laboratory) with 17 SAGE libraries (generated at the Polyak 
Laboratory, Dana-Farber Cancer Institute, Boston, MA, USA) down­
loaded from the Cancer Genome Anatomy Project — SAGE Genie 
database (http://cgap.nci.nih.gov/SAGE/). SAGE data management 
and tag-to-gene matching for RHBDD1 (AGGGCAGGGA), RHBDD2 
(TTGTCTGCCT), RHBDD3 (CTGCCCIAGT), RHBDL1 (TGGTGGCCGC), 
RHBDL2 (AGTTCAAGAC),RHBDL3 (TTGCTCCCCG), RHBDF1 (TGGCCAA- 
TAA), RHBDF2 (GATTAAATAA), and PARL (GCIATGCTCC) were per­
formed with a suite of web-based SAGE library annotation tools 
developed by us (http://spi.mdacc.tmc.edu/bitools/about/sage_lib_ 
tool.html). To enable the visualization and illustration of our analyses, 
we used the TIGR MultiExperiment Viewer (MeV 3.0) software (The 
Institute for Genomic Research, Rockville, MD, USA). This tool was 
employed for normalization and average clustering of the SAGE data.
2.2. RHBDD2 antibody production, Western-blot and 
immunofluorescence analyses
A polyclonal antibody against RHBDD2 was generated by sequen­
tial immunizations of two rabbits with three purified KLH-conjugated 
peptides (GenScript Corp., NJ, USA). Peptides were synthesized based 
on RHBDD2 protein sequence (NP065735) corresponding to residues 
30-43 (EDRQPASRRGAGTT), residues 253-266 (ASGAEARSDLPLQP), 
and residues 393-406 (HQGLQAPRSPPGSP). The polyclonal antibody 
was purified from the immune serum by affinity chromatography. The 
primary antibody specificity was further demonstrated by Western­
blot, immunofluorescence and siRNA analyses using breast cell lines 
(see below Figs. 2 and 6B).
Total protein extracts were prepared from a set of 7 breast normal 
and cancer cell lines (HME87, MCF10, MCF7, ZR75-30, T47D, BT47A, 
and BT549). As normal controls we also included human breast 
epithelial organoid protein extracts, obtained from three independent 
cosmetic mammoplastic specimens (B26, B27, and B28). Total cell 
protein lysates were made from frozen tissues using RIPA buffer 
(50 mM Tris pH 7.5, 150 mM NaCI, 0.5% sodium deoxycholate, 1% 
Triton X-100, and 0.1% SDS) containing protease inhibitor cocktail 
(Roche, Mannheim, Germany). For Western blot, 50 pg of total protein 
was separated by 12.5% SDS-PAGE and transferred to PVDF mem­
branes (Millipore, Billerica, MA). Immunodetection was performed 
using Protein Detector™ (KPL, Gaithersburg, MD) Western blotting 
reagents as described by the manufacturer. RHBDD2 protein was de­
tected using an anti-RHBDD2 polyclonal primary antibodies and HRP 
conjugated anti-rabbit secondary antibody (KPL, 1:2000) followed by 
chemiluminescence autoradiography. Beta-actin protein (ACTB) was 
detected using monoclonal anti-actin antibody (ICN Biomedicals, 
Burlingame, CA, 1:1000) and HRP conjugated anti-mouse secondary 
antibody (KPL, 1:5000).
For immunofluorescence analysis, MCF7 and MCF10 smears from 
exponentially growing cells were prepared on glass slides and then 
fixed in cold acetone for 10 min. Anti-RHBDD2 polyclonal antibody 
was added to the slides at a 1:250 dilution, and incubated at room 
temperature during 1 h. Detection was performed using FITC-labeled 
secondary anti-rabbit IgG antibodies following standard immuno­
fluorescence methods.
2.3. RT-PCR and cDNA sequencing analyses
Total RNA was isolated from eleven frozen normal breast tissue 
derived from cosmetic mammoplastic specimens and three breast 
cancer cell lines (MCF7, T47D and ZR75) using TRI Reagent® (MCR Inc., 
USA). Quality control of RNA integrity was made by running out 
RNA samples onto formaldehyde denaturing 1.2% agarose gel and 
ethidium bromide staining. Following DNAse I digestion, template 
cDNAs were synthesized using SuperScript™ First-strand Synthesis 
System (Invitrogen, USA). For mRNA expression analysis, we designed 
three combinations of PCR primers (Forward-1/Reverse, Forward-2/ 
Reverse, and Forward-3/Reverse) that spanned all exons of the 
RHBDD2 transcript. The primer sequences are as follows: Forward-1 
5'-CATCCGCCACCTTCTTCACT-3'; Forward-2 5'-GATCTTCGC- 
CATCTTCTCCG-3': Forward-3 5'-GCCTGATGAGGAGGATATCCG-3'; 
and Reverse 5'-AATACACCGTGCCAGGGCT-3'.
The isolated RT-PCR products were sequenced in both directions 
using the DYEnamic ET Dye Terminator Cycle Sequencing Kit and 
analyzed on a MEGABACE 1000 DNA sequencer (GE Healthcare 
Biosciences), according to the manufacturer's instructions. The 
obtained DNA sequences were further aligned and compared with 
the RHBDD2 genomic sequence (accession no. NT007933.14) to 
determine the exon-intron structure of RHBDD2. Experiments were 
performed in triplicate for each data point and beta-actin (ACTB) 
mRNA was used as reference.
2.4. Inmunohistochemistry analyses ofRHBDD2 protein expression 
in tissues
Formalin-fixed paraffin-embedded breast tissue samples were 
obtained from the MD Anderson Cancer Center — USA (61 samples), 
and from different hospitals associated to the National University of La 
Plata — Argentina (152 samples). The use of human tissue blocks and 
clinical records was approved by the appropriate institutional 
committees. By pooling both sample sets we were able to analyze a 
total of 213 cases including: 44 normal breast tissues (18 normal 
tissues from individuals without breast cancer, and 26 normal tissues 
adjacent to invasive breast cancers), 18 benign breast disease (7 benign 
mammary dysplasia, and 11 breast fibroadenomas), 26 ductal 
carcinomas in situ (DCIS), 109 primary invasive ductal carcinomas 
(IDC) and 16 lymph node metastasis specimens (LNM). Stage at time 
of diagnosis was based on the TNM classification.
Prior to immunostaining, endogenous peroxidase activity was 
blocked with 3% H202 in water for 10 min; heat-induced epitope 
retrieve was performed with 10 mM Citrate buffer pH 6.0 for 10 min in 
a microwave oven followed by a 20 min cool down. In order to block 
non-specific antibody binding, the slides were incubated with 10% goat 
serum in PBS for 30 min. Primary polyclonal RHBDD2 antibody was 
used at 1:250 dilution. Inmunodetection was performed with the 
DakoCytomation LSAB+ System-HRP (Dako, Denmark). Sections were 
counterstained with hematoxylin (Sigma, USA) and examined by light 
microscopy. Staining intensity was graded as negative ( —), weak ( + ), 
moderate ( + + ), or strong ( + + + ). The number of optical fields in a 
specimen that were positively stained was expressed as a percentage 
of the total number of optical fields containing tissue. A reaction was 
considered positive when more than 5% of the breast epithelial cells 
were stained. The staining of cytoplasm, plasma membrane and 
nucleus was evaluated; cells were considered positive when at least 
one of these components was stained. IHC analysis of ESRI (ER-alpha) 
was performed by using a primary monoclonal ERa antibody (ER-6F11, 
Novocastra — UK) at 1:50 dilution as was previously described [6].
2.5. RHBDD2 gene amplification analysis
DNA was isolated from 131 formalin-fixed paraffin-embedded 
samples (17 normal samples, 16 benign lesions and 98 invasive 
breast carcinomas) previously analyzed for RHBDD2 protein expres­
sion by IHC. RHBDD2 gene amplification was estimated using a 
competitive PCR method [7,8]. In the duplex PCR reactions, RHBDD2 
gene located at 7qll.23, and Solute carrier family 13A1 gene 
(SLC13A1, gene not known to be associated with cancer) located at 
7q31-q32, is used as the intra-chromosomal arm reference gene. 
SLC13A1 was chosen as reference gene because its chromosome 
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location (7q31-32) is lost in less than 2% of breast cancer cases based 
on array-CGH Progenetix database [9]. Duplex PCR amplification was 
done in a final volume of 50 pl using 10 ng of cDNA, 1.25 U of Taq DNA 
polymerase (Promega, Madison, Wisconsin — USA), 2.5 mM MgCI2, 
200 mM of each dNTP and 12.5 pmol of both primer pairs in PCR buffer 
(20 mM, Tris-HCL pH 8.4, and 50 mM KCL). The primers for both genes 
are RHBDD2-Forward 5'-CATCCGCCACCTTCTTCACT-3', RHBDD2- 
Reverse 5'-TGGTGATGAGGACCGAGACA-3' (amplicon of 259 bp), 
SLCUAl-Forward 5'-TCGCCGATTTCTCTTCGTG-3' and SLC13A1- 
Reverse 5'-GCCAGGCAGTTAAACAGCAAA-3' (amplicon of 157 bp). 
The reactions were cycled as follows: 1 cycle of 94 °C for 2 min; 
25 cycles of 40" at 92 °C, 40" at 57 °C, and 40" at 72 °C. Detection of the 
amplified fragments was made by electrophoresis onto a 2% agarose 
gel and SYBR-Safe™ DNA staining (Invitrogen — USA). The Kodak 
Digital Science ID Image Analysis Software was used to determine the 
ratio between net intensity bands of RHBDD2 and SLC13A1 amplicons. 
Samples were considered to be affected by genomic amplification for 
RHBDD2 when the ratio between net intensity bands was greater than 
+ 3 SD (99% confidence interval, p<0.001) relative to the average 
value determined from 11 normal breast control samples. Experi­
ments were performed in triplicate for each data point.
2.6. ¡n silico RHBDD2 gene expression and clinical data analysis
To further investigate correlations of transcriptional up-modula- 
tion of RHBDD2 gene and clinicopathologic parameters on larger 
breast carcinoma sets, data were obtained from a publicly available 
breast cancer microarray study [10]. Clinicopathologic and gene 
expression data from 295 primary invasive breast carcinomas (226 
ER-positive and 69 ER-negative carcinomas) were collected from the 
Rosetta Inpharmatics website (http://www.rii.com/publications/ 
2002/nejm.html). Two groups of patients were derived by using the 
median expression value of the Log2 ratio overall distribution for 
RHBDD2 probe (NM_020684) (RHBDD2 median = 0.017; high expres­
sion, greater than 0.017; and low expression, less than 0.017). Kaplan- 
Meier analysis was assessed with both groups using the Van de Vijver 
et al. data by means of SPSS® statistic software (SPSS Inc., Chicago).
2.7. RHBDD2 gene silencing and cell proliferation assay
Three siRNAs of 19-mer against RHBDD2 mRNA corresponding to 
coding sequences starting at positions 1326 (siRNA-Rl: 5'-CUGUGUU- 
GGGUACUUUGAUdTdT-3'), 340 (siRNA-R2: 5'-GUCUACGAGAAUCCC- 
AUCUdTdT-3') and 1050 (siRNA-R3: 5'-GCAGAACCACUUUGGUCCA- 
dtdt-3') relative to the cDNA sequence AF226732 were synthesized 
(Bioneer Inc, Korea). The AccuTarget™ biotin-labeled negative control
Fig. 2. RHBDD2 protein expression in normal and breast cancer cell lines. (A) Protein 
extracts were separated by 12.5% SDS-PAGE and transferred to PVDF membranes. 
RHBDD2 protein was detected using a polyclonal anti-RHBDD2 antibody developed by 
our laboratory. The membrane was then probed with mouse monoclonal anti-actin 
antibody for normalization of differences in protein loading. Three normal human 
protein extracts prepared from breast organoids were included (B25, B26, and B27). The 
full-length R.HBDD2 protein (isoform 1) and the predicted splicing variant (isoform 2) 
are indicated. (B) Immunofluorescence and immunocytochemistry detection of 
RHBDD2 displayed a vesicular pattern compatible with an ER-like distribution in 
MCF7 cells (see Supplementary Fig. 1). MCF10 cell smears were used as the negative 
control demonstrating non cross-reactivity of the primary antibody. MCF7 cells without 
RHBDD2 polyclonal antibody was also used as negative control of the reaction (MCF7- 
NegCt). The nuclei were counterstained with propidium iodide (red fluorescence).
siRNA (siRNA-NegCt: 5z-CCUACGCCACCAAUUUCGUdTdT-3z) (Bioneer 
Inc, Korea) that exhibits no homology to any human genome sequence 
was used as a non-silencing reference. In addition, we included a 
positive control siRNA sequence (Termo Scientific Dharmacon, USA),
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Fig. 1. Digital Northern analysis of human rhomboid-like family members based on SAGE data in 46 breast samples (4 normal breast epithelium, 8 ductal carcinoma in situ and 34 
invasive ductal carcinomas) (A). The color scale at the bottom of the picture is used to represent relative expression level based on numbers of transcripts (tags) per libraries. (B) 
ANOVA test of RHBDD2 expression among normal breast tissue, ductal carcinoma in situ (DCIS) and primary invasive breast carcinomas (IDC). High expression levels of RHBDD2 tag 
were detected in IDC compared with normal breast tissue group (p<0.008).
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A RHBDD2 mRNA
Isoform 1
Primers F1/R Primers F2/R Primers F3/R
- -1400 bp
Isoform 1^ RHBDD2
Isoform 2+
900 bp
ACTB
D
Isoformi 
Isoform2
CATCCGCCACCTTCTTCACTGCGCTGCTCTCGCTGCTGGTTTCCGGGCCTCGCCTGTTCCTGCTGCAGCAGCCCCTGGCGCCCTCGGGCCTCACGCTG71A
CATCCGCCACCTTCTTCACTGCGCTGCTCTCGCTGCTGGTTTCCGGGCCTCGCCTGTTCCTGCTGCAGCAGCCCCTGGCGCCCTCGGGCCTCACGCTGAA
EXON I
GTCCGAGGCCCTTCGCAACTGGCAAaCCACTATaaAAOaAGaGaTCAaGATTACAGCAaAGGAGACTQGCACACAaAGTOTTAAOTaACACCCACTCAAT 
GTCCGAGGCrCTTCGCAACTGGCA..............................................................................................................................................................................................................
CCACCCCGAAGCTGTTACACTTAATTAACCCTCAAACTGCCCAGTGAGTTTACAGGCTGGTAAOCTACATCTTTGTCTACGAGAATCCCATCTCCCTGCT
..............................................AGIrTACAGGCTGGTAACCTACATCTTTGTCTACGAGAATCCCATCTCCCTGCT
CTGCGGCGCTATCÄTCATCTGGCGCTTTGCTGGCÄATTTCGAGAGÄÄCCGTGGGCACCGTCCGCCÄCTGCTTCTTCÄCCGTGÄTCTTCGCCATCTTCTCC
CTGCGGCGCTATCATCATCTGGCGCTTTGCTGGCAATTTCGAGAGAACCGTGGGCÄCCGTCCGCCACTGCTTCTTCACCGTGATCTTCGCCATCTTCTCC
EXON III
GCTAICATCTTCCTGTCATTCGAGGCTGTGTCATCACTGTCAMGCTGGGGGAAGTGGAGGATGCCAGAGGTTTCACCCCAGTGGCCTTTGCCATGCTGG 
GCTATCATCTTCCTGTCATTCGAGGCTGTGTCATCACTGTCAAAGCTGGGGGAAGTGGAGGATGCCAGAGGTTTCACCCCAGTGGCCTTTGCCATGCTGG
GAGTCACCACCGTCCGTTCTCGGATGAGGCGGGCCCTGGTGTTTGGCATGGTTGTGCCCTCAGTCCTGGTTCCGTGGCTCCTGCTGGGTGCCTCGTGGCT 
GAGTCACCACCGTCCGTTCTCGGATGAGGCGGGCCCTGGTGTTTGGCATGGTTGTGCCCTCAGTCCTGGTTCCGTGGCTCCTGCTGGGTGCCTCGTGGCT
CÄTTCCCCAGACCTCTTTCCTCAGTAATGTCTGCGGGCTGTCCATCGGGCTGGCCTÄTGGCCTCACCTÄCTGCTÄTTCCATCGÄCCTCTCÄGAGCGAGTG
CATTCCCCAGACCTCTTTCCTCAGTAATGTCTGCGGGCTGTCCATCGGGCTGGCCTATGGCCTCACCTACTGCTATTCCATCGACCTCTCAGAGCGAGTG
F3 EXON IV
gcgctgaägctcgatcägäccttccccttcägcctgätgäggäggätatccgtgttcäagtäcgtctcägggtcttcägccgagäggägggcagcccägä
GCGCTGAAGCTCGATCÄGACCTTCCCCTTCäGCCTGATGAGGAGGATÄTCCGTGTTCAAGTACGTCTCAGGGTCTTCAGCCGÄGAGGAGGGCAGCCCÄGÄ
GCCGGAAACTGAACCCGGTGCCTGGCTCCTACCCCACACAGAGCTGCCACCCTCACCTGTCCCCAAGCCACCCTGTGTCCCAGACGCAGCACGCCAGTGG 
GCCGGAAACTGAACCCGGTGCCTGGCTCCTACCCCACACAGAGCTGCCACCCTCACCTGTCCCCÄAGCCACCCTGTGTCCCAGACGCAGCACGCCAGTGG
TCAGAÄGCTGGCCTCCTGGCCCTCCTGCÄCCCCCGGGCÄCATGCCCACCTTGCCTCCGTÄCCAGCCTGCCTCCGGCCTGTGCTATGTGCAGAÄCCACTTT
TCAGAAGCTGGCCTCCTGGCCCTCCTGCÄCCCCCGGGCACATGCCCACCTTGCCTCCGTACCAGCCTGCCTCCGGCCTGTGCTATGTGCAGAACCACTTT V
I sofarml
Isofomt2
GGTCCÄAACCCCACCTCCTCCAGTGTCTACCCAGCTTCTGCGGGCACCTCCCTGGGCATCCAGCCCCCCACGCCTGTGAACAGCCCTGGCACGGTGTATT 
GGTCCAAACCCCACCTCCTCCAGTGTCTACCCAGCTTCTGCGGGCACCTCCCTGGGCATCCAGCCCCCCACGCCTGTGAACAGCCCTGGCACGGTGTATT
Fig. 3. Identification of two RHBDD2 mRNA isoforms. (A) Schematic representation of human RHBDD2 genomic structure and the corresponding mRNA isoform structure predicted 
insilico based on RHBDD2 ESTdatabase searching. (B) RT-PCR analysis in MCF7,T47D, and ZR75 breast cancer cell lines. Three pairs of PCR primers (Fl / R, F2 / Rand F3 / R), based on 
EST sequences were used to amplify the RHBDD2 transcript from cDNA. Alternative splicing involving exons 1 and 2 generates the isoform 2. (C) RHBDD2 RT-PCR of five normal breast 
tissue (N1-N5) and three breast cancer cell lines (MCF7, T47D, ZR75). (D) Alignment of the MCF7 cDNA sequences among RHBDD2 isoforms.
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which significantly reduces the lamin A/C protein level by >70% 
without affecting the MCF7 cell phenotype or viability. MCF7 cells 
were seeded on 12 well plate format in Opti-MEM I Reduced Serum 
Medium (Invitrogen, USA), when cells reached 40% confluence, they 
were transfected with 40 pmoles/pl of siRNA mixed with TransIT- 
TKO® Transfection Reagent according to the manufacturer's protocol 
(Mirus, USA). Transfection efficiency was monitored using biotiny­
lated siRNA and FITC-avidin for detection. RHBDD2 mRNA and pro­
tein levels and effects on cells were analyzed by RT-PCR and 
immunofluorescence at 48 h post-transfection respectively. Cell 
proliferation was assessed using the CellTiter 96® Aqueous Non­
Radioactive Cell Proliferation Assay (Promega, USA), that is a colori­
metric method for determining the number of viable cells in pro­
liferation. In addition, cell viability was monitored daily by the trypan 
blue exclusion test.
2.8. Additional bioinformatics and statistical analyses
We employed the ASAP online database resource (Alternative 
Splicing Annotation Project) for the in silico analysis of RHBDD2 exon­
intron structure (http://www.bioinformatics.ucla.edu/ASAP). ASAP 
is based on human genome-wide analyses of alternative splicing 
events based on detailed alignment of EST/cDNA sequences onto the 
genomic sequence [11].
To enable visualization and illustration of the 7qll.2 chromosome 
region in some breast cancer cell lines from Pollack's array-CGH data 
[12], we used the VAMP software (Visualization and Analysis of array- 
CGH, transcriptome and other Molecular Profiles) (http: //bioinfo-out. 
curie.fr/actudb). VAMP is a graphical user interface for visualization 
and analysis of genomic profiles [13]. The chromosome 7 array-CGH 
profiles previously generated by Pollack et al. [12] from MCF7, T47D 
and ZR75 breast cancer cell lines were download from the ACTuDB 
database at the same website [14]. The frequency of DNAgains/losses 
affecting the chromosome region 7qll.23 was determined from a 
cumulative set of 552 1DC analyzed by array-CGH based on a publicly 
available Progenetix database (http://www.progenetix.net) [9[.
Univariate analysis of clinical-pathological parameters based on 
RHBDD2 gene amplification/expression was determined by Fisher's 
exact test. Ordinal-by-ordinal associations have been assessed by 
Kendall's tau-b test. The basic significance level was fixed at p< 0.05 
and all data were analyzed using SPSS® statistic software (SPSS Inc., 
Chicago).
3. Results
3.1. Human rhomboid family members expressed in breast epithelial cells
We analyzed the rhomboid-like family member gene expression 
profile in a set of normal and breast cancer SAGE libraries. Among the 
rhomboid family members, RHBDD2 and RHBDF1 were the most 
frequently expressed rhomboid-like genes in breast SAGE libraries 
(Fig. la). Specifically, RHBDD2 was detected as being expressed in 
100% of breast cancer cases (34 out of 34) according to SAGE database 
analyses, interestingly, among the rhomboid genes only RHBDD2 was 
identified as over-expressed in primary invasive breast carcinomas 
compared with normal breast samples (p<0.008) (Fig. lb). No 
association was detected between the expression of this transcript 
and ERu status (p>0.05).
3.2. RHBDD2 expression analysis in normal and breast cancer cell lines 
and identification of alternatively spliced mRNA isoforms
We performed Western-blot analysis in normal and breast cancer 
cell lines using a custom-design polyclonal antibody against the 
RHBDD2 protein. We identified the expected 47 kDa product as well as 
a smaller protein product at approximately 40 KDa. MCF7 and T47D 
cell lines showed high levels of RHBDD2 protein expression, while 
normal breast organoids (B26, B27, and B28) and non-transformed 
breast cell lines (MCF10A and HME87) showed weak and undetect­
able levels of RHBDD2 protein expression respectively (Fig. 2A). 
RHBDD2 immunostaining displayed a granulate/vesicular pattern 
compatible with an endoplasmic reticulum-like distribution with 
accumulation in the perinuclear space of MCF7 and T47D cells (Fig. 2B 
and Supplementary Fig. 1). MCF10 cell smears were used as the 
negative control of the reaction demonstrating non cross-reactivity of 
the primary antibody (Fig. 2B).
We decided to investigate whether the different protein products 
were results of alternatively spliced RHBDD2 transcripts (isoform). 
RHBDD2 alternative splicing prediction based on ASAP (Alternative 
Splicing Annotation Project) bioinformatics analysis revealed two 
putative isoforms, here named as isoform 1 (full-length RHBDD2 
mRNA) and isoform 2 (alternatively spliced isoform) (Fig. 3A). To 
validate these findings, we first performed an RT-PCR analysis in 
MCF7, T47D and ZR75 breast cancer cell lines. Three pairs of PCR 
primers, based on EST sequences were used to amplify the RHBDD2 
transcript from cDNA, and the products were sequenced. MCF7 and 
T47D cell lines showed high expression levels of RHBDD2 with any 
combination of PCR primers used for RT-PCR analysis (Fig. 3B, C). 
Interestingly, primer pairs Fl/R located on the first and last exons of 
RHBDD2 mRNA respectively, result in two PCR products of approxi­
mately 1100 and 900 bp in MCF7 and T47D cell lines (Fig. 3A). The 
luminal-tumor derived cell line ZR75 showed weak RHBDD2 mRNA 
expression. However, primer pairs F2/R and F3/R result in a unique 
RT-PCR product of 720 bp and 369 bp respectively as it was expected 
(Fig. 3B, C) and confirmed by direct DNA sequencing (data not 
shown). Bi-directional sequence analysis was performed on each 
purified RT-PCR product from the MCF7 cell line. Comparison of these 
sequences with the publicly available RHBDD2 genomic sequence 
(accession no. NT007933.14) confirmed gene identity for each PCR 
fragment and revealed that these two transcripts detected with the 
primer pairs Fl/R were generated by alternative RNA splicing of exons 
1 and 2 of RHBDD2 (Fig. 3D). These data suggest that the low protein 
product observed in the Western-blot analysis represents true 
RHBDD2 protein, demonstrating that the antibody used in our study 
detected the full-length RHBDD2 protein (isoform 1) as well as the 
alternative splicing variant (isoform 2) (Fig. 2). In addition, this RT- 
PCR analysis showed undetectable or low expression of RHBDD2 gene 
in normal breast tissues analyzed (Fig. 3C). These data corroborate the 
SAGE analysis showing that RHBDD2 mRNA/protein expression is 
highly elevated in some breast cancer cells compared with normal 
breast samples.
3.3. Increased RHBDD2 protein expression in breast cancer clinical 
specimens
To further investigate the relevance of RHBDD2 protein expres­
sion in breast cancer, we analyzed 213 breast tissue sections by 
immunohistochemistry (Table 1 and Fig. 4). We identified a statis­
tical significant increase in RHBDD2 protein expression from normal
Table 1
R.HBDD2 protein expression in breast samples as related to histopathological 
characteristics.
Histopathology Protein expression n (%) Cases
Absent Weak Moderate Strong
Normal epithelium 13 (72%) 4(22%) 0 (0%) 1 (6%) 18
Normal adjacent IDC 4 (15%) 4 (15%) 12 (46%) 6 (23%) 26
Benign lesions 6 (33%) 6(33%) 4 (22%) 2 (11%) 18
DCIS 1 (4%) 7(27%) 11 (42%) 7 (27%) 26
IDC 31 (28%) 34 (31%) 23 (21%) 21 (20%) 109
LNM 0 (0%) 4(25%) 4 (25%) 8 (50%) 16
Total 55 59 54 45 213
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Fig- 4. RHBDD2 immunohistochemical staining in (A) normal breast adjacent tumor (xlOO), (B) hyperplastic breast lesion (xlOO), (C) ductal carcinoma in situ 1x400;, (D, E) ERct- 
negative invasive ductal carcinomas with RHBDD2 gene amplification (xlOO and x400 respectively), and (F) lymph node metastasis sample (x400). As negative control for 
immunohistochemical staining we used a tissue sample, without primary antibody incubation (G), derived from serial sections of a RHBDD2-positive invasive breast carcinoma (H).
breast tissues to breast cancer metastasis specimens analyzed 
(p-trend = 0.01).
RHBDD2 protein expression was detected in 61% (27 out of 44) of 
normal breast samples analyzed. Interestingly, 95% (17 out of 18) of 
normal breast epithelium obtained from cosmetic mammoplasties, 
showed negative or weak RHBDD2 protein expression (Table 1). In 
contrast, 69% (18 out of 26) of normal breast tissue adjacent to 
invasive ductal carcinomas showed moderate or strong RHBDD2 
expression, and only 31% (8 out of 26) of these samples showed 
negative or weak RHBDD2 immunostaining (Table 1). Statistical ana­
lysis of RHBDD2 protein expression between normal breast epi­
thelium and normal breast adjacent IDC showed highly significant 
differences (p = 0.0001). RHBDD2 immunostaining showed a granu­
late reaction that was mostly localized in the perinuclear space and in 
the membrane.
Benign mammary dysplasia and fibroadenoma lesions displayed 
negative or weak RHBDD2 protein expression in approximately 66% 
(12 out of 18) of the analyzed cases, while moderate or strong 
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RHBDD2 protein expression was predominantly detected in 69% 
(18 out of 26) of the ductal carcinomas in situ analyzed (p<0.01) 
(Table 1).
Among IDC samples, negative RHBDD2 expression was detected in 
28% of the cases (31 out of 109). However, when RHBDD2 expression 
and tumor stage were considered, we observed a statistically 
significant correlation between high levels of RHBDD2 and more 
clinically advanced cancer (p = 0.001). In this sense, 92% of IDC 
negative for RHBDD2 expression were early-stage (I and II) breast 
carcinomas while only 9% of tumor stage III were negative for RHBDD2 
protein expression. Furthermore, 50% of IDC with tumor stage III 
showed moderate or strong RHBDD2 protein expression. Interestingly, 
RHBDD2 protein expression was detected in all breast lymph node 
metastasis samples (16 out of 16) displaying a moderate or strong 
RHBDD2 expression in approximately 75% (12 out of 16) of the 
analyzed samples (Table 1 and Fig. 4). Non-statistical significant 
association was detected between RHBDD2 protein expression and 
ERa status as well as histologic tumor grade (p>0.05).
Overall, these data are in agreement with the SAGE profiling 
analysis, indicating that a high proportion of invasive breast carcino­
mas expressed significantly increased levels of RHBDD2 protein 
compared with normal breast samples. More importantly, strong 
RHBDD2 protein expression was highly associated with primary in­
vasive breast carcinomas with axillary lymph node metastases.
3.4. RHBDD2 gene is amplified in correlation with over-expression in 
breast cancer cells
Microarray-based comparative genomic hybridization evidence is 
available reporting the amplification of the chromosomal region 
7qll.23 in breast cancer cell lines and primary breast carcinomas 
[12,15]. To investigate the frequency of DNAgains/losses affecting the 
chromosome region 7qll.23, we performed a pooled re-analysis of 
552 invasive breast carcinomas previously analyzed by array-CGH, 
available at Progenetix online database. Pooled estimates showed gain 
of chromosome region 7qll.23 in 11% of the analyzed cases (61 out of 
552 IDC). The Visualization and Analysis of array-CGH, transcriptome 
and other Molecular Profiles (VAMP) [13] resource was employed for 
microarray-CGH data analysis of chromosome region 7qll.23 from 
MCF7, T47D and ZR75 breast cancer cell lines. In silico analysis of 
Pollack's data [14] identified a gain of chromosome regions 7qll.22- 
7qll.23 including the RHBDD2 gene region in MCF7 and T47D cell 
lines (Fig. 5A). These data are in agreement with our Western-blot 
observations.
We used a competitive PCR method based on duplex PCR of 
RHBDD2 (target) and SLC13A1 (control) genes for the quick inter­
rogation of human breast tumor DNA for the presence or absence of 
genomic amplification of specific genes affecting the region of 
interest. We analyzed DNA obtained from breast cancer cell lines 
and 131 samples (17 normal tissues, 16 benign lesions, 98 IDC) 
previously analyzed for protein expression by IHC. The DNAs from all 
samples were adequately amplified by the SLC13A1 control primers. 
Competitive PCR analysis showed RHBDD2 gene amplification in 
MCF7 and T47D breast cancer cell lines, while no amplification was 
detected for the ZR75 cancer line, in agreement with the array-CGH 
data and validating the method (Fig. 5B). It is important to note, 
that RHBDD2 mRNA and protein expression are highly elevated in 
both breast cancer cell lines (MCF7 and T47D), thus confirming a 
direct association between RHBDD2 gene amplification and over­
expression. RHBDD2 genomic amplification was detected in 21%
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Fig. 5. RHBDD2 gene amplification analysis in breast samples. (A) Visualization of 7qll.2 microarray-based CGH profile of MCF7, T47D and ZR.75 breast cancer cell lines obtained from 
Pollack et al. study [12], Red lines indicate chromosomal regions of gain. These data suggest a region of genomic gain located at 7qll.23 involving the RHBDD2 gene. (B) RG-PCR assay 
showed RHBDD2 gene amplification in MCF7 and T47D breast cancer cell lines in agreement with Pollack data. (C) DNA sequence chromatogram of isolated PCR amplicons 
confirming the RHBDD2 and SLC13A1 gene sequence identities. (D) RG-PCR analysis in normal breast tissues (N1-N5), and seven primary invasive breast carcinomas. Note that three 
invasive breast carcinomas (samples 996,1516 and 1495) showed RHBDD2 gene amplification (black arrows).
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D
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(21 out of 98) primary invasive breast carcinomas analyzed (Fig. 5D). 
However, no amplification in RHBDD2 was identified in any of 17 
normal and 16 benign tissue samples analyzed. Statistical analysis 
identified a significant positive association between RHBDD2 gene 
amplification and RHBDD2 protein expression assessed by IHC 
studies (p<0.05).
3.5. RHBDD2 gene silencing in vitro leads to reduced cell proliferation 
rate
To investigate whether RHBDD2 gene expression plays any role 
associated to cell proliferation; a knock-down assay was performed 
with specific siRNA sequences targeting RHBDD2 mRNA in MCF7 
breast cancer cell line. Cells were treated with optimal concentrations 
of RHBDD2 siRNA and examined the number of viable cells 48 h after 
transfection.
RT-PCR and immunofluorescence analyses demonstrated an 
effective depletion of RHBDD2 at mRNA and protein levels in MCF7 
by using the siRNA-Rl and siRNA-R3 sequences compared with the 
negative control siRNA (Fig. 6A and B). MCF7 cells in the control 
group were treated with the siRNA-Ct, which had a randomized 
nucleotide sequence that had no significant homology to the human 
genome. siRNA-Rl and siRNA-R3 treated cells showed a significant 
decrease in proliferation 48 h after transfection compared to 
negative or positive control siRNAs (Fig. 6C). In addition, siRNA-Rl 
and siRNA-R3 treatments did not affect cell viability or morphology 
of MCF7 breast cancer cells. This result suggests that RHBDD2 
function is related to regulation of cell proliferation in MCF7 breast 
cancer cells.
3.6. RHBDD2 expression analysis and its clinical relevance as 
poor-prognosis marker
To further explore the clinical relevance of gene expression in 
human breast carcinomas, we evaluated information from publicly 
available breast cancer gene expression data sets (microarrays). 
Because the estrogen receptor plays a critical role in breast cancer, 
we first analyzed gene expression profiles of RHBDD2 relative to ERa 
status. Statistical analysis showed that RHBDD2 expression was not 
associated with ERa status of primary breast carcinomas (p = 0.148). 
This result is in agreement with our previously described data 
regarding RHBDD2 gene/protein expression in primary breast carci­
nomas obtained by SAGE and IHC studies.
Next, we analyzed RHBDD2 expression with patient's outcome 
using the microarray data set of Van de Vijver et al [10]. 
Interestingly, we identified a significant association between high 
expression of RHBDD2 and short time relapse-free survival among 
295 patients (p = 0.018; Fig. 7A). Kaplan-Meier analysis revealed 
that RHBDD2 over-expression was particularly associated with 
shorter overall survival (p = 0.0023; Fig. 7B), metastasis-free 
interval (p = 0.006; Fig. 7C), and relapse-free survival (p = 0.013; 
Fig. 7D) but surprisingly only in patients with ERa-negative breast 
carcinomas. Non-statistically significant associations were found for 
RHBDD2 expression and follow-up in patients with ERa-positive 
carcinomas (p>0.05).
4. Discussion
In a recent study using SAGE, we performed a comparative global 
gene expression profile of primary invasive breast carcinomas [1].
•*  " siRNA-Ct
♦
Fig. 6. RHBDD2 knock-down analysis in MCF7 breast cancer cell line. (A) RT-PCR analysis of RHBDD2 and (3-actin (ACTS) mRNAs in AccuTarget™ negative control siRNA (siRNA-Ct) 
and three RHBDD2 siRNA sequence treatments (siRNA-Rl, siRNA-R2 and siRNA-R3). (B) Immunofluorescence analysis of RHBDD2 protein expression (green fluorescence) in siRNA- 
Ct, siRNA-Rl and siRNA-R3 treatments. The nuclei were counterstained with propidium iodide (red fluorescence). (C) Analysis of relative proliferation rates in MCF7 breast cancer 
cells at 48 h after siRNA transfection, expressed as absorbances at 492 nm measured using the CellTiter 96® AQueous Non-Radioactive Cell Proliferation Assay (Promega, USA). Each 
point represents the mean ±2 SE of 12 replicates.
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Fig. 7. RHBDD2 gene expression profile and breast cancer patient follow-up based on a publicly available DNA microarray data set. (A) Relapse-free survival of 295 patients grouped 
according to low or high RHBDD2 gene expression levels of the primary invasive breast carcinomas (226 ERa-positive and 69 ERct-negative breast samples). Kaplan-Meier curves of 
overall survival (B), metastasis-free interval (C), and relapse-free survival (D) of 69 patients with ERct-negative primary invasive breast carcinomas based on high or low expression 
levels of RHBDD2 gene. Kaplan-Meier analysis was assessed using the Van de Vijver et al. data set [10],
Unsupervised statistical analysis identified two main breast clusters 
carcinoma which differed in their lymph node status, suggesting 
that lymph node status leads to a global distinct expression profile. 
In this study, we identified a rhomboid-like family member gene 
known as RHBDD2 to be up-regulated in lymph node (+) breast 
carcinomas compared with lymph node ( —) counterparts. Real-time 
RT-PCR analysis of an independent set of breast carcinomas 
demonstrated statistically significant RHBDD2 over-expression in 
the primary breast cancers from patients that recurred within 
6 years of follow-up [1].
In the present study, we first determined the human rhomboid­
like family member gene expression profile in a set of 46 normal and 
breast carcinoma SAGE libraries. We found that the RHBDD2 transcript 
was readily detectable in almost all primary invasive breast carcinoma 
and over-expressed compared to normal breast samples. In addition, a 
second human rhomboid-like gene, RHBDF1 (Rhomboid family-1 
gene), was identified as highly expressed in primary invasive breast 
SAGE libraries. Interestingly, in a recent study Yan et al. showed that 
RHBDF1 is significantly elevated in invasive ductal carcinomas at both 
mRNA and protein levels, and also seems important for breast cancer 
cell growth in vivo and in vitro [16].
We further explored RHBDD2 protein expression in 213 breast 
tissue samples by immunohistochemistry. This study confirmed the 
SAGE observations, showing that RHBDD2 protein is highly 
expressed in primary invasive breast carcinoma stage III and 
lymph node metastasis. However, this study also found that 
RHBDD2 was highly expressed in some DCIS, suggesting that 
RHBDD2 expression may occur early in the development of cancer. 
Interestingly, we detected that normal breast tissue adjacent to 
invasive breast carcinomas showed moderate or strong RHBDD2 
expression while normal breast epithelium from mammoplastic 
specimens showed to be predominantly negative for RHBDD2 
expression. This observation of abnormal high RHBDD2 expression 
in mammary epithelium adjacent to cancer allows us to speculate 
that expression of this protein could be influenced by the tumor 
microenvironment. It is possible that autocrine or paracrine stimuli 
maybe operative in modulating RHBDD2 expression in mammary 
epithelial cells.
Tumor-specific up-regulation of some genes can be attributed to 
aberrant DNA amplification, a phenomenon frequently found in many 
breast tumors [12]. Usually genomic amplification in cancer involves 
genes that provide some sort of growth advantage or transformation 
to the cells bearing the amplification. Typically amplification involves 
growth factors, growth factor receptors, certain cyclins, transcription 
factors or co-activators, i.e. positive regulators of proliferation and by 
definition many are dubbed oncogenes. Interestingly, microarray­
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based comparative genomic hybridization evidence is available 
reporting amplification of the chromosomal region 7qll.2 (the same 
region to which RHBDD2 maps) in breast cancer cell lines and primary 
breast carcinomas [12,15]. Moreover, a genome-wide transcriptome 
map revealed clusters of genes located at 7qll.2 exhibiting non­
random increased expression in breast cancer cells [17]. To determine 
whether RHBDD2 was also amplified and over-expressed in breast 
tumors, we studied 98 primary invasive breast carcinomas for gene 
amplification and protein expression by RG-PCR and IHC respectively. 
RHBDD2 was amplified in 21% of the analyzed samples. Although, 
almost all amplified samples showed moderate to strong RHBDD2 
protein expression, some breast carcinomas showed over-expression 
of RHBDD2 in the absence of gene amplification, suggesting in addi­
tion an up-regulation of expression by transcriptional regulatory 
means. We also determined that RHBDD2 over-expression in cell lines 
MCF7 and T47D was likely the result of amplification of chromosome 
region 7qll.23. In addition, we identified and characterized the 
expression of two alternative spliced RHBDD2 mRNA isoforms in these 
breast cancer cell lines.
Interestingly, in a recent study Yan et al. demonstrated that 
abrogation of RHBDF1 expression in MDA-MB435 cells and in head 
and neck squamous cancer cell line 1483 leads to inhibition of cell 
proliferation. siRNA-mediated RHBDF1 silencing results in apoptosis 
in breast cancer cells and inhibition of xenograft tumor growth in vivo 
[16]. More importantly, in a very recently study Zou et al. demon­
strated that RHBDF1 participates in the modulation of G protein- 
coupled receptor-mediated EGFR transactivation. Furthermore, 
RHBDF1 over-expression in head and neck cancer cells results in 
facilitated export ofTGFa [18]. These data suggest that RHBDF1 plays a 
critical role in the mechanism responsible for the production of 
activated EGFR ligand. Similar to the observations of Yan et al. [16] in 
our studies we found that siRNA-mediated silencing of RHBDD2 
expression in MCF7 breast cancer cell line leads to a marked decrease 
in cell proliferation. Thus, the possibility exists that RHBDD2 may also 
play a role in signaling pathways related to cell proliferation/survival 
as shown for RHDBF1; as such it could be a protein of relevance in 
breast cancer initiation and progression. Interestingly, and supporting 
this speculation, in silico analyses revealed that patients whose 
tumors expressed high RHBDD2 had significantly shorter relapse- 
free survival when compared with those whose tumors had low 
RHBDD2 levels. More importantly, we found that high RHBDD2 
expression was significantly associated with shorter overall survival, 
relapse-free survival, and metastasis-free interval in patients with 
ERa-negative breast carcinomas. These data are in line with our 
observation that increased RHBDD2 protein expression is associated 
with advanced tumor stages. In addition, we further confirmed our 
initial finding in which we observed a statistically significant over­
expression of RHBDD2 in primary tumors of patients who after follow­
up developed recurrent disease [1], In summary, our findings indicate 
that RHBDD2 over-expression might play a role in breast cancer tumor 
progression facilitating the development of more aggressive pheno­
types in at least a subset of breast carcinomas. Further studies are 
required to elucidate the exact role of this protein in breast cancer.
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